Curcumin-Loaded Liposomes (hPLipo/Cur) with Liver-Targeting Properties for Efficient NAFLD Treatment by Alleviating Mitochondrial ROS-Mediated Ferroptosis via NRF2 Pathway
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Xue Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210002, Chin…. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Liposomes, Curcumin, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Funding for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University.
Abstract (Originalsprache)
NAFLD is a rising health problem worldwide with unsatisfied therapies. Curcumin has an ameliorative but limited effect on NAFLD due to its low water solubility. In this study, we innovatively establish the high-PC-content liposome-loaded curcumin (hPLipo/Cur) with liver-targeting properties for NAFLD therapy. hPLipo/Cur, composed of DSPC, cholesterol, and DSPE-PEG 2000, has better biocompatibility and water solubility and is loaded with curcumin with high efficiency. hPLipo/Cur is superior to curcumin in improving hepatic histology, as evidenced by reducing lipid deposition and macrophage infiltration in steatohepatitis. Mechanistically, hPLipo/Cur reduces NRF2 degradation and promotes the nuclear translocation of NRF2, as well as the expression of downstream antioxidant genes. The activated NRF2 pathway reduces cellular oxidative stress and the generation of mitochondrial ROS, thereby reducing the accumulation of lipid peroxides and inhibiting ferroptosis in steatohepatitis. In conclusion, hPLipo/Cur reduces mitochondrial ROS-mediated ferroptosis by enhancing the NRF2 pathway to alleviate steatohepatitis, providing a promising strategy for NAFLD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210002, China.
- Department of Prosthodontics, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210002, China.
- Department of Gastroenterology and Hepatology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210002, China.
- Department of Gastroenterology, Nanjing Drum Tower Hospital, Clinical College, Jiangsu University, Zhenjiang, Jiangsu 212000, China.
- Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210002, China.
ORCID-Profile: Bing Xu
Förderung
- National Natural Science Foundation of China
- Funding for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University
Zitieren
APA
Wang, X., Fang, R., Zhao, T., Ding, L., Cai, M., Zhang, D., Xu, N., Yang, S., Zhao, S., Zhang, H., Xie, X., Zhang, Z., Zhang, M., Zhang, L., Zhuge, Y., & Xu, B. (2026). Curcumin-Loaded Liposomes (hPLipo/Cur) with Liver-Targeting Properties for Efficient NAFLD Treatment by Alleviating Mitochondrial ROS-Mediated Ferroptosis via NRF2 Pathway. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01400
Vancouver
Wang X, Fang R, Zhao T, Ding L, Cai M, Zhang D, et al. Curcumin-Loaded Liposomes (hPLipo/Cur) with Liver-Targeting Properties for Efficient NAFLD Treatment by Alleviating Mitochondrial ROS-Mediated Ferroptosis via NRF2 Pathway. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01400
BibTeX
@article{Wang2026,
author = {Wang, Xue and Fang, Rui and Zhao, Tianming and Ding, Ling and Cai, Mengxi and Zhang, Dongbo and Xu, Nuo and Yang, Suzhen and Zhao, Si and Zhang, Han and Xie, Xiaolin and Zhang, Zhiheng and Zhang, Ming and Zhang, Li and Zhuge, Yuzheng and Xu, Bing},
title = {Curcumin-Loaded Liposomes (hPLipo/Cur) with Liver-Targeting Properties for Efficient NAFLD Treatment by Alleviating Mitochondrial ROS-Mediated Ferroptosis via NRF2 Pathway},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01400}
}
EUVIMED